Pi Network tested AI image recognition on nodes with OpenMind, using idle CPU power during its ongoing Mainnet upgrade phase. The network requires Mainnet nodesPi Network tested AI image recognition on nodes with OpenMind, using idle CPU power during its ongoing Mainnet upgrade phase. The network requires Mainnet nodes

Pi Network Tests AI Computing on Nodes Ahead of Pi Day DEX Launch

For feedback or concerns regarding this content, please contact us at [email protected]
  • Pi Network tested AI image recognition on nodes with OpenMind, using idle CPU power during its ongoing Mainnet upgrade phase.
  • The network requires Mainnet nodes to upgrade to v20.2 by March 12 as part of its path toward version 23.0 in Q2 this year.

Pi Network is testing artificial intelligence workloads on its node network as it moves through a required Mainnet upgrade path ahead of its planned Pi Day DEX launch. The project has ordered node operators to complete the move to version 20.2 by March 12. This step forms part of a broader roadmap that aims to take the network to version 23.0 in the second quarter of 2026.

The upgrade process follows a fixed sequence. Node operators must move through versions 19.1, 19.6, 19.9, 20.2, 21.1, 22.1, and 23.0 in order. Recently, we covered that Pi Network completed its Protocol v19.9 migration and is preparing to roll out v20.2. 

The network requires all Mainnet nodes to complete that step before the March 12 deadline. Nodes that do not update in time risk losing their network connection.

This structured path supports the next stage of Pi Network’s development. The rollout is tied to technical preparation for Pi Day, when the project expects to introduce a new decentralized exchange. At the same time, the team is testing whether its node system can take on tasks beyond transaction validation.

During the upgrade phase, Pi Network has run a case study with OpenMind to test AI computing on node machines. The trial used node computers to process object recognition tasks through image analysis. Results were returned within seconds, showing that the system could complete basic AI workloads by using distributed computing power across the network.

The test points to a broader use case for the node network. Many Pi nodes run on personal computers with unused CPU capacity. That idle power can be directed toward lightweight AI tasks rather than being left unused. This model turns the network into a distributed computing system that could support both blockchain activity and selected AI functions.

Most recently, CNF reported that Pi Network marked the first anniversary of its Open Network by outlining new priorities around AI tools, KYC, and ecosystem tokens.

Pi Network Merges Upgrade Path and AI Utility

The project’s broader plan links infrastructure maturity with new utility. The version 23.0 target for Q2 2026 reflects a wider push to expand the network’s role. Pi Network is preparing its ecosystem for both exchange-related activity and computing services tied to decentralized participation.

The AI trial also adds a new layer to the project’s utility model. If the concept moves beyond testing, node operators may eventually contribute processing power for AI workloads and receive Pi-based rewards. That model would allow users to keep running node software while supporting image recognition or similar tasks through spare computing capacity.

Pi Network already reports more than 350,000 nodes and millions of KYC-verified users worldwide. In February, we reported that it was testing its KYC validator rewards distribution system after completing the design and implementation stages.

]]>
Market Opportunity
Pi Network Logo
Pi Network Price(PI)
$0.22856
$0.22856$0.22856
+15.38%
USD
Pi Network (PI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09